10-QPeriod: Q2 FY2024

AGILENT TECHNOLOGIES, INC. Quarterly Report for Q2 Ended Apr 30, 2024

Filed June 3, 2024For Securities:A

Summary

Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and first six months of fiscal year 2024, down 8% and 7% respectively, compared to the prior year. This decline was primarily driven by the Life Sciences and Applied Markets segment and the Diagnostics and Genomics segment, impacted by customer capital expenditure pressures, particularly in the pharmaceutical market. The Agilent CrossLab segment showed resilience with revenue growth in both periods. Despite the revenue decline, net income remained stable, with $308 million reported for the third quarter and $656 million for the first six months, slightly up from the prior year. Operating cash flow significantly improved, reaching $818 million for the first six months of fiscal year 2024, up from $694 million in the comparable prior-year period. The company also announced a new restructuring plan (FY24 Plan) aimed at further cost reductions, involving approximately 500 employee reductions, with an estimated annual cost savings of $100 million. Additionally, a new $2.0 billion share repurchase program was approved, effective August 1, 2024.

Financial Highlights

57 data points
Beta

Revenue

$1.57B

54.4% Gross Margin

Net Income

$308.00M

19.6% Net Margin

EPS (Diluted)

$1.05

Total Assets

$10.86B

Cash & Equivalents

$1.67B

Free Cash Flow

$230.00M

Financial Statements
Beta
Revenue$1.57B
Cost of Revenue$717.00M
Gross Profit$856.00M
R&D Expenses$113.00M
SG&A Expenses$380.00M
Operating Expenses$1.21B
Operating Income$363.00M
Interest Expense$20.00M
Net Income$308.00M
EPS (Basic)$1.05
EPS (Diluted)$1.05
Shares Outstanding (Basic)293.00M
Shares Outstanding (Diluted)293.00M

Key Highlights

  • 1Net revenue decreased by 8% year-over-year for the third quarter and 7% for the first six months of fiscal year 2024.
  • 2Life Sciences and Applied Markets and Diagnostics and Genomics segments experienced revenue declines, while Agilent CrossLab saw growth.
  • 3Net income remained stable year-over-year, with $308 million for Q3 FY24 and $656 million for the first six months of FY24.
  • 4Operating cash flow increased significantly to $818 million for the first six months of FY24, up from $694 million in the prior year.
  • 5The company announced a new restructuring plan (FY24 Plan) targeting approximately 500 employee reductions for further cost savings.
  • 6A new $2.0 billion share repurchase program was authorized, effective August 1, 2024.
  • 7The company continues to face capital expenditure pressures from customers, particularly in the pharmaceutical market.

Frequently Asked Questions

Agilent's revenue declined primarily due to decreases in its Life Sciences and Applied Markets and Diagnostics and Genomics segments. This was largely influenced by customers' continued capital expenditure pressures, particularly within the pharmaceutical market, and a significant decline in revenue in China.

Despite the revenue decline, Agilent's net income remained stable year-over-year, indicating effective cost management and a favorable business mix. The Agilent CrossLab segment's growth also helped offset declines in other segments. Furthermore, operating cash flow saw a significant improvement.

Agilent announced a new restructuring plan (FY24 Plan) involving a reduction of approximately 500 employees, which is expected to yield approximately $100 million in annual cost savings. They also continue to implement targeted pricing and other cost-saving strategies to mitigate inflationary pressures.

The Life Sciences and Applied Markets and Diagnostics and Genomics segments are expected to continue facing revenue challenges due to customer capital expenditure pressures and market conditions. However, the Agilent CrossLab segment is well-positioned for continued success and growth due to the demand for its services and its diversified geographic presence.